### Indonesia

**Population 2018** 268 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total TB incidence</strong></td>
<td>845 (770–923)</td>
<td>316 (288–345)</td>
</tr>
<tr>
<td><strong>HIV-positive TB incidence</strong></td>
<td>21 (8.9–38)</td>
<td>7.9 (3.3–14)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>24 (17–32)</td>
<td>8.8 (6.2–12)</td>
</tr>
<tr>
<td><strong>HIV-negative TB mortality</strong></td>
<td>93 (67–99)</td>
<td>35 (33–37)</td>
</tr>
<tr>
<td><strong>HIV-positive TB mortality</strong></td>
<td>5.3 (2.1–9.8)</td>
<td>2 (0.79–3.7)</td>
</tr>
</tbody>
</table>

### Tuberculosis profile

#### Estimates of TB burden, 2018

- **New cases**: 2.4% (1.8–3.3)
- **Previously treated cases**: 13% (9–18)

#### TB case notifications, 2018

- **Total new and relapse**: 563,879
  - % tested with rapid diagnostics at time of diagnosis: 12%
  - % with known HIV status: 37%
  - % pulmonary: 88%
  - % bacteriologically confirmed**: 50%
  - % children aged 0-14 years: 11%
  - % women: 37%
  - % men: 52%
- **Total cases notified**: 570,289

### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2018**: 67% (61–73)
- **TB patients facing catastrophic total costs**: 12% (10–13)

### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**:
  - New cases: 33%
  - Previously treated cases: 127%

### Notified cases by age group and sex, 2018

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>05-14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-34</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35-44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Treatment success rate and cohort size

- **New and relapse cases registered in 2017**: 85% 425,819
- **Previously treated cases, excluding relapse, registered in 2017**: 73% 4,934
- **HIV-positive TB cases registered in 2017**: 69% 7,966
- **MDR/RR-TB cases started on second-line treatment in 2016**: 48% 1,905
- **XDR-TB cases started on second-line treatment in 2016**: 21% 61

### TB preventative treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 10%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 10% (9.3–11)

### TB financing, 2019

- **National TB budget (US$ millions)**: 365
- Funding source: 30% domestic, 13% international, 57% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-02-28

Data: www.who.int/tb/data